SCHEMBL5439628

SCHEMBL5439628

CCC(c1ccccc1)c1nnc(NC(=O)Nc2ccc(C)c(Cl)c2)s1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.53
HTT P42858 3/20 0.53
MAPT P10636 4/20 0.50
LMNA P02545 3/20 0.50
RAB9A P51151 4/20 0.49
EPHX2 P34913 1/20 0.47
NPC1 O15118 4/20 0.47
BLM P54132 1/20 0.47
NTRK1 P04629 1/20 0.47
NTRK2 Q16620 1/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 1/20 0.47
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5439968 0.87 MEN1 (0.73) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL5441202 0.85 MEN1 (0.57) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL3467489 0.78 MEN1 (0.76) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL3468752 0.78 HTT (0.62) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL5440007 0.75 KMT2A (0.61) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL5446613 0.74 MEN1 (0.69) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL4111390 0.74 SMN1; SMN2 (0.75) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL2184232 0.73 MEN1 (0.84) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL5456028 0.73 MEN1 (0.78) MEN1KMT2ASMN1; SMN2HTTMAPT
SCHEMBL3467876 0.73 SMN1; SMN2 (0.58) MEN1KMT2ASMN1; SMN2HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191353-A1 Use of thiadiazoleurea derivatives MERCK PATENT GMBH (DE) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191353-A1 Use of thiadiazoleurea derivatives RAF1, ARAF, JAK1 MEN1 1756/4885KMT2A 1865/4885SMN1; SMN2 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.